PMC7098965_01
G-banding analysis of the BM sample at relapse, which showed the balanced translocation t(8;17)(q12;p11.2). (B) FISH with a chromosome 17 centromere probe (green) and a TP53 probe (red) showed one of the TP53 signals on the der chromosome, suggesting that the chromosome 17p breakpoint is centromeric to TP53 on 17p13. (C) RT-PCR showed various levels of NCOR1-LYN fusion transcript in bone marrow specimens. Lane 1: relapse sample; lane 2: 2 weeks after dasatinib; lane 3: 1 month post allo-HSCT; lane 4: 2 months post allo-HSCT; lane 5: 3 months post allo-HSCT; lane 6: 10 months post allo-HSCT; lane 7: negative control. (D) Sanger sequencing result of the NCOR1-LYN fusion gene, confirming a fusion between exon 34 of NCOR1 and exon 8 of LYN. (E) Schematic representation of the predicted domain structure of the NCOR1-LYN fusion.
fonc-10-00359-g0001.jpg
PMC7098965_02_fonc-10-00359-g0001.jpg
F1
RT-PCR assays showed significantly decreased fusion transcript (Figure 1C). He has been tolerated with dasatinib very well and remained in MRD negative remission for 10 months now post allo-HSCT, based on both flow cytometry and RT-PCR assays (Figure 1C). Timeline of the treatment was shown in Supplementary Figure 1.
NGS analysis of the bone marrow sample at relapse showed deletions of CDKN2A and IKZF1. (B,C) Bone marrow smears before and after dasatinib therapy.
fonc-10-00359-g0002.jpg
PMC7098965_02_fonc-10-00359-g0002.jpg
F2
After completion of chemotherapy, bone marrow morphology still showed 61.5% of blasts (Figure 2B). Two weeks after dasatinib treatment, bone marrow aspirates showed only 1% of blasts by histology (Figure 2C) and 0.1% of blasts by flow cytometry.
PMC7098965_02
G-banding analysis of the BM sample at relapse, which showed the balanced translocation t(8;17)(q12;p11.2). (B) FISH with a chromosome 17 centromere probe (green) and a TP53 probe (red) showed one of the TP53 signals on the der chromosome, suggesting that the chromosome 17p breakpoint is centromeric to TP53 on 17p13. (C) RT-PCR showed various levels of NCOR1-LYN fusion transcript in bone marrow specimens. Lane 1: relapse sample; lane 2: 2 weeks after dasatinib; lane 3: 1 month post allo-HSCT; lane 4: 2 months post allo-HSCT; lane 5: 3 months post allo-HSCT; lane 6: 10 months post allo-HSCT; lane 7: negative control. (D) Sanger sequencing result of the NCOR1-LYN fusion gene, confirming a fusion between exon 34 of NCOR1 and exon 8 of LYN. (E) Schematic representation of the predicted domain structure of the NCOR1-LYN fusion.
fonc-10-00359-g0001.jpg
PMC7098965_02_fonc-10-00359-g0001.jpg
F1
RT-PCR assays showed significantly decreased fusion transcript (Figure 1C). He has been tolerated with dasatinib very well and remained in MRD negative remission for 10 months now post allo-HSCT, based on both flow cytometry and RT-PCR assays (Figure 1C). Timeline of the treatment was shown in Supplementary Figure 1.
NGS analysis of the bone marrow sample at relapse showed deletions of CDKN2A and IKZF1. (B,C) Bone marrow smears before and after dasatinib therapy.
fonc-10-00359-g0002.jpg
PMC7098965_02_fonc-10-00359-g0002.jpg
F2
After completion of chemotherapy, bone marrow morphology still showed 61.5% of blasts (Figure 2B). Two weeks after dasatinib treatment, bone marrow aspirates showed only 1% of blasts by histology (Figure 2C) and 0.1% of blasts by flow cytometry.